A phase 3 clinical trial of SkQ1 compound Visomitin for dry eye disease has been initiated, Mitotech announced in a press release.
The topical ophthalmic formulation is designed to reduce oxidative stress within the mitochondria, the release said. The phase 3 multicenter, randomized, double-masked, placebo-controlled study will include two SkQ1 treatment arms and a placebo arm.
“Very few drugs with truly innovative mechanisms of action reach this stage of clinical development in dry eye,” Mitotech CEO Natalia Perekhvatova said in the release. “Dry eye disease is a